Navigation Links
K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice
Date:12/7/2011

Management's Discussion and Analysis of Financial Condition and Results of Operations—Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011, including:

(a) the consent decree between the Company and the FDA and the Company's suspension in 2008 and 2009 of the production and shipment and the nationwide recall of all of the products that it formerly manufactured, as well as the related material adverse effect on our revenue, assets and liquidity and capital resources;

(b) the agreement between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") to resolve the risk of potential exclusion of the Company from participation in federal healthcare programs; and

(c) our ability to comply with the plea agreement between a  now-dissolved subsidiary of the Company and the U.S. Department of Justice;

(5) the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;

(6) risks that the Company may not ultimately prevail in, or that insurance proceeds, if any, will be insufficient to cover potential losses that may arise from, litigation discussed in Note 16—"Commitments and Contingencies—Litigation and Governmental Inquiries" of the Notes to the Consolidated Financial Statements included in Part I, Item 1 of our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011, including:

(a) the series of putative class action lawsuits alleging violations of the federal securities laws by the Company and certain individuals; 

(b) product liability lawsuits;

(c) lawsuits pertaining to indemnification and employment agreement obligations involving the Company and its former Chief Executive Officer;

'/>"/>
SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
2. Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting
3. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
4. Unity Management Group, Inc. Receives Contract From Sun Pharmaceutical Indias Largest Pharmaceutical Companies for $105,000
5. Global Pharmaceutical Services Company Turns to Glowpoints OpenVideo™ Cloud
6. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
7. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
8. UHC Launches RxLINK™, Gives Hospitals Unprecedented Insight Into Pharmaceutical Pricing
9. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
10. Par Pharmaceutical to Host Analyst Day on January 6, 2012
11. Radient Pharmaceuticals Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... BERLIN , April 28, 2015 ... universities of Berlin and the ... Berlin as a central research location ... of scientific, technical and medical information products and services, ... Charité, the Humboldt University (Humboldt-Universität), the Free University ...
(Date:4/28/2015)... , April 28, 2015 ANI Pharmaceuticals, Inc. ... plans to release its first quarter 2015 financial results ... the U.S. financial markets. The earnings press release will ... Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
(Date:4/28/2015)... , April 28, 2015 /CNW/ - The group representing the ... drug tragedy left a two-hour meeting with Health Canada ... March 6th, Health Canada announced a $180 million support ... than six weeks after the Health Canada announcement and ... fully support the victims, the group representing ...
Breaking Medicine Technology:Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 2Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 3ANI Pharmaceuticals Schedules Conference Call for First Quarter 2015 Financial Results 2Thalidomide Victims Gravely Concerned by Health Canada's Silence 2
... control versus Concerta from 30 minutes to six hours post-dose in ... as 30 minutes post-dose, - Additional analysis suggests Focalin XR provides comparable efficacy ... Concerta ... impact a child,s ability to focus and learn in an educational ...
... ANA773 Acting via ... ... July 7 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) announced today ... for the,treatment of chronic hepatitis C. Based on preclinical pharmacology testing,and ...
Cached Medicine Technology:Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 2Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 3Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 4Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 5Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 6Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 7Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day 8Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5
(Date:4/28/2015)... NY (PRWEB) April 28, 2015 ... management (IdM/IAM) solutions, announces today that they have ... of the top ten Identity and Access Management ... of the top Identity and Access Management tools ... quarter of 2015 and analyzed their trends to ...
(Date:4/28/2015)... 28, 2015 A new survey from ... lung damage, 66 percent of Americans fear brain damage the ... Awareness Month in May, shed light on the need for ... help prevent a stroke. By controlling modifiable risk factors, ... stroke is a “ brain attack ” that occurs when ...
(Date:4/28/2015)... CA (PRWEB) April 28, 2015 ... the Journal of Molecular Imaging and Biology showed ... a 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor. ... Hopkins University in Baltimore, MD by study co-author, ... initial human evaluation of [18F]DCFPyL demonstrated a number ...
(Date:4/28/2015)... Colorado spine surgeon Donald Corenman, MD, DC has ... education website NECKANDBACK.COM and his back pain ... website has been redesigned to help patients gain a ... of neck and back pain, and conditions and treatments ... answers questions in the neck and back pain forum ...
(Date:4/28/2015)... Everett, WA (PRWEB) April 28, 2015 Dead ... for owners and their property. In many cases, tree removal ... most efficient way to eliminate the threat. , ... various types of tree removal available to property owners today. ... can provide for a job well done. , The article ...
Breaking Medicine News(10 mins):Health News:Tools4ever Chosen as Part of “Top Identity and Access Management Tools - 2015 Edition” 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 2Health News:National Stroke Association Survey Reveals Americans Fear Brain Damage the Most, but Few Take the Necessary Steps to Prevent a Stroke 3Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 2Health News:Second Generation 18F-labeled Prostate-Specific Membrane Antigen (PSMA) Targeted Imaging Agent Found to be Highly Sensitive in Detecting Prostate Cancer 3Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 2Health News:Colorado Spine Surgeon Donald Corenman, MD, DC Launches Updated Version of NECKANDBACK.COM and Popular Back Pain Forum ASKSPINEDOC.COM 3Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2
... , LONDON, July 13 The market for most ... sales are geared towards the replacement of older systems. Global conglomerates, ... dominate the market. However, there are many small regional vendors that ... in Europe. Innovation will be critical for success in this market. ...
... 13 Uroplasty, Inc. (NYSE Amex: UPI ... markets innovative proprietary products for the treatment of voiding ... No. 7,536,226 entitled, "Electro-Nerve Stimulator System and Methods." The ... methods for treatment of the overactive bladder ("OAB") symptoms ...
... , BEVERLY HILLS, Calif., July 13 Michael Jackson,s ... across America via top TV networks, thanks to PR Whiz Belinda ... joined forces via world media outlets strategized by PR Whiz, Foster, ... drug addict, but rather a chronic insomniac. , ...
... ... , ... 13, 2009 -- Upsher-Smith announces updates to its Website, www.prenexa.com . PreNexa® is the ... prenatal vitamins taken once a day.(1-4) , ,The updated content and offerings on prenexa.com ...
... ... ... 2009 -- Omnetics Connector Corporation , the leading manufacturer of nano-miniature ruggedized connectors, ... miniature electrical connectors. Their proprietary process of terminating signals and grounds on separate ...
... ... and Technology at Online Radiology Medical Group, Inc. (ONRAD), is excited to announce the launch ... ... and Technology at Online Radiology Medical Group, Inc. (ONRAD), is excited to announce the launch ...
Cached Medicine News:Health News:Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders, Advises Frost & Sullivan 2Health News:Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders, Advises Frost & Sullivan 3Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 2Health News:Uroplasty Announces Patent Issuance Related to the Urgent(R) PC System 3Health News:PR Whiz Belinda Foster Launches Michael Jackson's Nurse, Cherilyn Lee, on World Media Campaign 2Health News:Upsher-Smith Laboratories, Inc. Updates Prenexa.com with Folic Acid Content, Money-Saving Coupon, and Personalized Address Labels 2Health News:Omnetics' Multi-Contact Nano Connectors Obtain Digital Transmission Rates Over 2 Gb/sec. 2
... PRODUCT SPECIFICATIONS Form: Granular, free-flowing powder EEO (-m r ... (3%): less than or equal to 35C Remelt Point ... (3%): greater than or equal to 300 gm/cm 2 ... less than or equal to 0.10% DNase: Passes test ...
... Form: Granular, free-flowing powder EEO(-m r ): less ... less than or equal to 35.5C Remelt Point (3%): ... (1.5%): greater than or equal to 600 gm/cm ... or equal to 1500 gm/cm 2 Moisture: ...
... traces: chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ... mg/kg Cd ≤ 5 mg/kg Co ≤ 5 mg/kg ... ≤ 10 mg/kg K ≤ 50 mg/kg Mg ≤ ... mg/kg Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg ...
... Anion traces: chloride (Cl) ≤ 3000 mg/kg sulfate (SO ... 500 mg/kg Cd ≤ 10 mg/kg Co ≤ 10 ... Fe ≤ 10 mg/kg K ≤ 500 mg/kg Mg ... 5000 mg/kg Ni ≤ 10 mg/kg Pb ≤ 10 ...
Medicine Products: